Miltefosine Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 10 mg, 50 mg
Reference Brands: Impavido (USA/EU)
Category:
Anti-fungal
Miltefosine is an oral antiprotozoal agent used to treat visceral, cutaneous, and mucosal leishmaniasis. It works by disrupting cell membrane phospholipid metabolism in Leishmania parasites, leading to parasite death. It is also used as part of combination therapy for rare amoebic infections. The treatment is taken orally for several weeks and requires monitoring for gastrointestinal effects and liver or kidney function changes. It should not be used during pregnancy due to teratogenic risks.
Miltefosine is available in Capsules
and strengths such as 10 mg, 50 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Miltefosine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Miltefosine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing